Art

J-GLOBAL ID：202002243084018709   Reference number：20A2807635

Current Status and Future Perspectives of Companion Diagnostics

コンパニオン診断薬の現状と今後の展望

Author (3)： TSUKUMO YOSHINORI (国立医薬品食品衛研) ,  SUZUKI TAKAYOSHI (国立医薬品食品衛研) ,  INOUE TAKAO (国立医薬品食品衛研)
Material： 医薬品医療機器レギュラトリーサイエンス  (Pharmaceutical and Medical Device Regulatory Science)
Volume： 51  Issue： 12  Page： 638-648  Publication year： Dec. 10, 2020 
JST Material Number： F0456B  ISSN： 1884-6076  CODEN： IIKRA9  Document type： Article
Article type： 文献レビュー  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human ,...
Semi thesaurus term： genetic variation ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A2807635&from=J-GLOBAL&jstjournalNo=F0456B") }}

JST classification (3)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Clinical application of diagnostic drugs  (GW20020A) ,  Gene manipulation  (EC02050B)

Reference (32)：

• Gleevec approval letter, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_Approv.pdf.
• Druker, BJ.; Talpaz, M.; Resta, DJ.; Peng, B.; Buchdunger, E.; Ford, JM.; Lydon, NB.; Kantarjian, H.; Capdeville, R; Ohno-Jones, S.; Sawyers, CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344(14), p.1031-1037.
• Druker, BJ.; Sawyers, CL.; Kantarjian, H.; Resta, DJ.; Reese, SF.; Ford, JM.; Capdeville, R.; Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344 (14), p.1038-1042.
• Paez, JG.; Jänne, PA.; Lee, JC.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, FJ.; Lindeman, N.; Boggon, TJ.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, MJ.; Sellers, WR.; Johnson, BE.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304 (5676), p.1497-1500.
• Mitsudomi, T.; Kosaka, T.; Endoh, H.; Horio, Y.; Hida, T.; Mori, S.; Hatooka, S.; Shinoda, M.; Takahashi, T.; Yatabe, Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005, 23 (11), p.2513-2520.

Terms in the title (3)： コンパニオン診断薬 ,  現状 ,  展望